Abstract | OBJECTIVE: DESIGN: A prospective open-label, flexible dosing, 3-week study period with a 5-week extension. SETTING: PATIENTS: Twenty subjects with a diagnosis of idiopathic distal sensory polyneuropathy (with or without associated impaired glucose tolerance), with a baseline mean pain daily rating of > or =4 on a visual analog scale. Intervention. Lidocaine patch 5%, maximum of four patches daily for 18 hours. MAIN OUTCOME MEASURE: Change from baseline week to week 3 mean daily diary pain ratings. Secondary endpoints included assessments of safety and tolerability as well as quality of life measures. RESULTS: Subjects with idiopathic distal sensory polyneuropathy, both with and without impaired glucose tolerance, showed significant improvements in pain and quality of life outcome measures over a 3-week treatment period. These improvements were maintained in a subgroup of patients treated for an additional 5 weeks and permitted a taper of concomitant analgesics in 25% of subjects. The lidocaine patch 5% was well tolerated. CONCLUSIONS:
|
Authors | David N Herrmann, Richard L Barbano, Stephanie Hart-Gouleau, Janet Pennella-Vaughan, Robert H Dworkin |
Journal | Pain medicine (Malden, Mass.)
(Pain Med)
2005 Sep-Oct
Vol. 6
Issue 5
Pg. 379-84
ISSN: 1526-2375 [Print] England |
PMID | 16266359
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anesthetics, Local
- Lidocaine
|
Topics |
- Administration, Topical
- Anesthetics, Local
(administration & dosage, adverse effects)
- Humans
- Lidocaine
(administration & dosage, adverse effects)
- Neuralgia
(drug therapy)
- Neurons, Afferent
- Polyneuropathies
(drug therapy)
- Prospective Studies
- Quality of Life
- Treatment Outcome
|